Novartis extends Galvus resubmission target to mid-‘09
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
An FDA-requested safety study of Novartis' antidiabetic Galvus (vildagliptin) will take at least six months, not "weeks" as the firm originally suggested, and will enroll "several hundred" patients with renal impairment, Head of Pharma Development James Shannon tells a July 17 earnings call. The study, requested in FDA's Feb. 23 "approvable" letter for the dipeptidyl peptidase-4 agent, responds to concerns about skin lesions seen in primates and healthy volunteers at four to six times the proposed therapeutic dose, Shannon said. FDA is concerned that susceptible populations may get to those levels, he explained. FDA has requested that all manufacturers developing DPP-4 agents characterize their compounds' dermatologic safety profiles (1Pharmaceutical Approvals Monthly March 2007, p. 20). Novartis submitted a study protocol in June and, if FDA agrees, anticipates starting the renal impairment study in the fourth quarter of 2007. "We would resubmit the dossier to the FDA sometime in mid-2009," Shannon predicted…
You may also be interested in...
Novartis Galvus "approvable"
Novartis will likely have to conduct another clinical trial of its dipeptidyl peptidase-4 inhibitor Galvus (vildagliptin) following a Feb. 23 "approvable" letter. FDA had earlier requested a three-month extension of the initial November 2006 user fee date due to concerns about necrotoxicity seen in preclinical studies. Novartis said FDA remains concerned about the skin toxicity and that some patients may be predisposed to achieving high plasma levels with standard doses. FDA requested that all manufacturers developing DPP-4 agents characterize their compounds' dermatologic safety profiles. Cleared in October, FDA did not see skin toxicity in Merck's Januvia (sitagliptin), which was the first DPP-4 inhibitor to be approved (1Pharmaceutical Approvals Monthly January 2007, p. 29)...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.